INTERVENTIONAL, EFFICACY, SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OPEN-LABEL EXT
Clinical Trial Grant
Administered By
Pediatrics, Neurology
Awarded By
Pfizer, Inc.
Start Date
March 27, 2025
End Date
July 30, 2027
Administered By
Pediatrics, Neurology
Awarded By
Pfizer, Inc.
Start Date
March 27, 2025
End Date
July 30, 2027